Extensive analysis of the clinical datasets29 revealed that the overexpression of CBFB confers an accelerated disease progression and shortened overall survival periods not only to AML patients but also to various types of cancers (Fig. 6f and Supplementary Fig. S6). This evidence concerns the gene CBFB and acute myeloid leukemia.